| Kirstin Anne Redefer, | |
|
1 Grenoble Pl, Rehoboth Beach, DE 19971-2847 | |
| (302) 226-2691 | |
| Not Available |
| Full Name | Kirstin Anne Redefer |
|---|---|
| Gender | Female |
| Speciality | Physical Therapy |
| Experience | 5 Years |
| Location | 1 Grenoble Pl, Rehoboth Beach, Delaware |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215569280 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2251X0800X | Physical Therapist - Orthopedic | J1-0004182 (Delaware) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Elite Pt Rb Llc | 3971973249 | 9 |
News Archive
Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Pradaxa® (dabigatran etexilate mesylate) for the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have been treated with a parenteral anticoagulant for five to 10 days, and to reduce the risk of recurrent DVT and PE in patients who have been previously treated. DVT and PE are collectively referred to as venous thromboembolism (VTE).
Viruses have evolved a broad range of strategies that enable them to evade the immune systems of their hosts. A team of researchers led by LMU virologist Professor J-rgen Haas has been studying a novel, recently discovered mechanism that pathogenic viruses exploit for this purpose, and their latest results could point the way to new antiviral therapies. The mechanism is based on the production of short RNA molecules, called microRNAs, by the virus.
IntraPace, Inc. announced today that it has received CE Mark for the LGL102, a new gastric stimulation/food sensing lead designed to work with the innovative abiliti system, an implantable weight loss management system.
About 30% of breast cancer patients have tumours that show rapid growth and invasion through the body. A common denominator in all of these cases is the presence of a large number of Her2 proteins in tumour cellular membranes. Consequently, these aggressive tumours are referred to as HER2+. Scientists working in the Metastasis Laboratory (MetLab) at IRB Barcelona headed by ICREA researcher Roger Gomis, have described the molecular mechanism that induces HER2+ tumours to ignore the signals that protect cells from excessive growth.
› Verified 3 days ago
| Provider Name | Elite Pt Llc |
|---|---|
| Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Provider Identifiers | NPI Number: 1063684041 PECOS PAC ID: 7315032711 Enrollment ID: O20071001000219 |
News Archive
Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Pradaxa® (dabigatran etexilate mesylate) for the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have been treated with a parenteral anticoagulant for five to 10 days, and to reduce the risk of recurrent DVT and PE in patients who have been previously treated. DVT and PE are collectively referred to as venous thromboembolism (VTE).
Viruses have evolved a broad range of strategies that enable them to evade the immune systems of their hosts. A team of researchers led by LMU virologist Professor J-rgen Haas has been studying a novel, recently discovered mechanism that pathogenic viruses exploit for this purpose, and their latest results could point the way to new antiviral therapies. The mechanism is based on the production of short RNA molecules, called microRNAs, by the virus.
IntraPace, Inc. announced today that it has received CE Mark for the LGL102, a new gastric stimulation/food sensing lead designed to work with the innovative abiliti system, an implantable weight loss management system.
About 30% of breast cancer patients have tumours that show rapid growth and invasion through the body. A common denominator in all of these cases is the presence of a large number of Her2 proteins in tumour cellular membranes. Consequently, these aggressive tumours are referred to as HER2+. Scientists working in the Metastasis Laboratory (MetLab) at IRB Barcelona headed by ICREA researcher Roger Gomis, have described the molecular mechanism that induces HER2+ tumours to ignore the signals that protect cells from excessive growth.
› Verified 3 days ago
| Provider Name | Elite Pt Rb Llc |
|---|---|
| Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Provider Identifiers | NPI Number: 1053028597 PECOS PAC ID: 3971973249 Enrollment ID: O20221230002091 |
News Archive
Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Pradaxa® (dabigatran etexilate mesylate) for the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have been treated with a parenteral anticoagulant for five to 10 days, and to reduce the risk of recurrent DVT and PE in patients who have been previously treated. DVT and PE are collectively referred to as venous thromboembolism (VTE).
Viruses have evolved a broad range of strategies that enable them to evade the immune systems of their hosts. A team of researchers led by LMU virologist Professor J-rgen Haas has been studying a novel, recently discovered mechanism that pathogenic viruses exploit for this purpose, and their latest results could point the way to new antiviral therapies. The mechanism is based on the production of short RNA molecules, called microRNAs, by the virus.
IntraPace, Inc. announced today that it has received CE Mark for the LGL102, a new gastric stimulation/food sensing lead designed to work with the innovative abiliti system, an implantable weight loss management system.
About 30% of breast cancer patients have tumours that show rapid growth and invasion through the body. A common denominator in all of these cases is the presence of a large number of Her2 proteins in tumour cellular membranes. Consequently, these aggressive tumours are referred to as HER2+. Scientists working in the Metastasis Laboratory (MetLab) at IRB Barcelona headed by ICREA researcher Roger Gomis, have described the molecular mechanism that induces HER2+ tumours to ignore the signals that protect cells from excessive growth.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kirstin Anne Redefer, 33274 Harbor Reach Dr, Lewes, DE 19958-4660 Ph: () - | Kirstin Anne Redefer, 1 Grenoble Pl, Rehoboth Beach, DE 19971-2847 Ph: (302) 226-2691 |
News Archive
Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Pradaxa® (dabigatran etexilate mesylate) for the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have been treated with a parenteral anticoagulant for five to 10 days, and to reduce the risk of recurrent DVT and PE in patients who have been previously treated. DVT and PE are collectively referred to as venous thromboembolism (VTE).
Viruses have evolved a broad range of strategies that enable them to evade the immune systems of their hosts. A team of researchers led by LMU virologist Professor J-rgen Haas has been studying a novel, recently discovered mechanism that pathogenic viruses exploit for this purpose, and their latest results could point the way to new antiviral therapies. The mechanism is based on the production of short RNA molecules, called microRNAs, by the virus.
IntraPace, Inc. announced today that it has received CE Mark for the LGL102, a new gastric stimulation/food sensing lead designed to work with the innovative abiliti system, an implantable weight loss management system.
About 30% of breast cancer patients have tumours that show rapid growth and invasion through the body. A common denominator in all of these cases is the presence of a large number of Her2 proteins in tumour cellular membranes. Consequently, these aggressive tumours are referred to as HER2+. Scientists working in the Metastasis Laboratory (MetLab) at IRB Barcelona headed by ICREA researcher Roger Gomis, have described the molecular mechanism that induces HER2+ tumours to ignore the signals that protect cells from excessive growth.
› Verified 3 days ago
Pivot Physical Therapy Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 37155 Rehoboth Ext, Rehoboth Beach, DE 19971 Phone: 302-227-2008 | |
Ms. Karen Elizabeth Yuen, M.P.T. Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 19266 Coastal Hwy, Rehoboth Beach, DE 19971 Phone: 302-226-2230 Fax: 302-227-7065 | |
Dynamic Therapy Services, Llc Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 37155 Rehoboth Avenue Ext, Rehoboth Beach, DE 19971 Phone: 302-227-2008 Fax: 302-227-8098 | |
Elite Pt Llc Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1 Grenoble Pl, Rehoboth Beach, DE 19971 Phone: 302-226-2691 Fax: 302-226-2692 | |
Mrs. Marguerite Recicar, M.P.T. Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 3 Black Duck Reach, Rehoboth Beach, DE 19971 Phone: 302-226-4796 | |
Elite Pt Llc Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1 Grenoble Pl, Rehoboth Beach, DE 19971 Phone: 302-226-2691 Fax: 302-226-2692 |